TrialPharmacology research & perspectives2026

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Highly Selective NaV1.8 Inhibitor JKN2306 in Healthy Chinese Subjects.

Ying Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.